Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial
Posted inNeurology news Pediatrics

Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial

The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical development due to a negative benefit-risk profile.
The Psychological Burden of Watchful Waiting: Anxiety and Depression Linked to Increased Rupture Risk and Mortality in Unruptured Intracranial Aneurysms
Posted inNeurology news Psychiatry

The Psychological Burden of Watchful Waiting: Anxiety and Depression Linked to Increased Rupture Risk and Mortality in Unruptured Intracranial Aneurysms

A large-scale retrospective study reveals that anxiety and depression following the diagnosis of unruptured intracranial aneurysms significantly increase the risk of rupture and all-cause mortality, suggesting that integrated psychiatric assessment is a critical component of neurovascular management.
Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study
Posted inNeurology news Psychiatry

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention's feasibility and safety, providing crucial effect size estimates for future neuroprotective research.
Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial
Posted inInternal Medicine Neurology news

Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial

The EMPHASIS trial reveals that oral minocycline initiated within 72 hours of an acute ischaemic stroke significantly enhances functional independence at 90 days. This multicentre study provides robust evidence for a well-tolerated, accessible neuroprotective strategy beyond the traditional reperfusion window.